

CLAIMS

1. An isolated dual binding antibody that binds IL-13 and TSLP comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3, and said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3, wherein the amino acid sequences of the HCDRs and the LCDRs of said antibody are selected from any one of the following sets:
 - (a) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 384;
 - (b) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 365;
 - (c) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 361;
 - (d) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,

- LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 371;
- (e) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 384;
- (f) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 363;
- (g) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 368;
- (h) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;
- (i) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,

- HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 372;
- (j) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 373;
- (k) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 374;
- (l) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 376;
- (m) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 377;

- (n) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 378;
- (o) HCDR1 comprises the amino acid sequences amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;
- (p) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 380;
- (q) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;
- (r) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 381;

- (s) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;
- (t) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 382;
- (u) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;
- (v) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 383;
- (w) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,

- LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 385;
- (x) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 386;
- (y) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 387;
- (z) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 388;
- (aa) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 389;

- (bb) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;
- (cc) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 390;
- (dd) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 391;
- (ee) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 392;
- (ff) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 393;

- (gg) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 394;
- (hh) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 395;
- (ii) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 396;
- (jj) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 397;
- (kk) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;

- (ll) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 388;
- (mm) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 394;
- (nn) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;
- (oo) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 399;
- (pp) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 400;

- (qq) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;
- (rr) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 378;
- (ss) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 401;
- (tt) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 402;
- (uu) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 403;

- (vv) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 376;
- (ww) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 402;
- (xx) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 360, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 404;
- (yy) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 405;
- (zz) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 406;

- (aaa) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 407; and
- (bbb) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355,
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,
LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,
LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 367, and
LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379.
2. The isolated dual binding antibody of claim 1, wherein said VH and said VL
comprise the amino acid sequences set forth in SEQ ID NOs:337 and 338,
respectively; SEQ ID NOs:213 and 214, respectively; SEQ ID NOs:209 and 210,
respectively; SEQ ID NOs:219 and 220, respectively; SEQ ID NOs:249 and 250,
respectively; SEQ ID NOs:211 and 212, respectively; SEQ ID NOs:215 and 216,
respectively; SEQ ID NOs:217 and 218, respectively; SEQ ID NOs:221 and 222,
respectively; SEQ ID NOs:223 and 224, respectively; SEQ ID NOs:225 and 226,
respectively; SEQ ID NOs:227 and 228, respectively; SEQ ID NOs:229 and 230,
respectively; SEQ ID NOs:231 and 232, respectively; SEQ ID NOs:233 and 234,
respectively; SEQ ID NOs:235 and 236, respectively; SEQ ID NOs:237 and 238,
respectively; SEQ ID NOs:239 and 240, respectively; SEQ ID NOs:241 and 242,
respectively; SEQ ID NOs:243 and 244, respectively; SEQ ID NOs:245 and 246,
respectively; SEQ ID NOs:247 and 248, respectively; SEQ ID NOs:251 and 252,
respectively; SEQ ID NOs:253 and 254, respectively; SEQ ID NOs:255 and 256,
respectively; SEQ ID NOs:257 and 258, respectively; SEQ ID NOs:259 and 260,
respectively; SEQ ID NOs:261 and 262, respectively; SEQ ID NOs:263 and 264,
respectively; SEQ ID NOs:265 and 266, respectively; SEQ ID NOs:267 and 268,
respectively; SEQ ID NOs:269 and 270, respectively; SEQ ID NOs:271 and 272,

respectively; SEQ ID NOs:273 and 274, respectively; SEQ ID NOs:275 and 276, respectively; SEQ ID NOs:277 and 278, respectively; SEQ ID NOs:279 and 280, respectively; SEQ ID NOs:281 and 282, respectively; SEQ ID NOs:283 and 284, respectively; SEQ ID NOs:285 and 286, respectively; SEQ ID NOs:287 and 288, respectively; SEQ ID NOs:289 and 290, respectively; SEQ ID NOs:291 and 292, respectively; SEQ ID NOs:293 and 294, respectively; SEQ ID NOs:295 and 296, respectively; SEQ ID NOs:297 and 298, respectively; SEQ ID NOs:299 and 300, respectively; SEQ ID NOs:301 and 302, respectively; SEQ ID NOs:303 and 304, respectively; SEQ ID NOs:305 and 306, respectively; SEQ ID NOs:307 and 308, respectively; SEQ ID NOs:309 and 310, respectively; SEQ ID NOs:311 and 312, respectively; SEQ ID NOs:313 and 314, respectively; SEQ ID NOs:315 and 316, respectively; SEQ ID NOs:317 and 318, respectively; SEQ ID NOs:319 and 320, respectively; SEQ ID NOs:321 and 322, respectively; SEQ ID NOs:323 and 324, respectively; SEQ ID NOs:325 and 326, respectively; SEQ ID NOs:327 and 328, respectively; SEQ ID NOs:329 and 330, respectively; SEQ ID NOs:331 and 332, respectively; SEQ ID NOs:333 and 334, respectively; SEQ ID NOs:335 and 336, respectively; SEQ ID NOs:337 and 338, respectively; SEQ ID NOs:339 and 340, respectively; SEQ ID NOs:341 and 342, respectively; SEQ ID NOs:343 and 344, respectively; SEQ ID NOs:345 and 346, respectively; or SEQ ID NOs:347 and 348, respectively.

3. The isolated dual binding antibody of claim 1 or claim 2, wherein said antibody comprises an IgG, an Fv, an scFv, an Fab, an F(ab')₂, a minibody, a diabody, or a triabody.
4. The isolated dual binding antibody of claim 3, wherein said IgG is IgG1, IgG2, IgG3, or IgG4.
5. The isolated dual binding antibody of claim 3 or claim 4, wherein said IgG comprises a heavy chain (HC) comprising a mutation that reduces binding to an Fc receptor, wherein said dual binding antibody comprising this mutation is unable to bind to antibody-dependent cellular cytotoxicity components.

6. The isolated dual binding antibody of claim 5, wherein said mutation is a L234A L235A P329G (LALAPG) mutation or a L234A L235A (LALA) mutation.
7. The isolated dual binding antibody of claim 5 or claim 6, wherein said VH and said VL comprise the amino acid sequences set forth in SEQ ID NOs:337 and 338, respectively, and said antibody comprises said L234A L235A P329G (LALAPG) mutation.
8. The isolated dual binding antibody of claim 5 or claim 6, wherein said VH and said VL comprise the amino acid sequences set forth in SEQ ID NOs:337 and 338, respectively, and said antibody comprises said L234A L235A (LALA) mutation.
9. A composition comprising the isolated dual binding antibody that binds IL-13 and TSLP of any one of claims 1-8 and a pharmaceutically acceptable carrier.
10. An isolated polynucleotide construct encoding the isolated dual binding antibody that binds IL-13 and TSLP of any one of claims 1-8.
11. An expression vector comprising the polynucleotide construct of claim 10.
12. A host cell comprising the expression vector of claim 11.
13. The isolated dual binding antibody that binds IL-13 and TSLP of any one of claims 1-8 for use as a medicament.
14. Use of a composition comprising an isolated dual binding antibody that binds IL-13 and TSLP of any one of claims 1-8 in the preparation of a medicament for the treatment of a disease or condition associated with IL-13 and/or TSLP signaling, wherein said disease or condition is an allergic or respiratory condition, an inflammatory or autoimmune condition, or tumors or cancers.
15. The use of claim 14, wherein said disease or condition is asthma, allergic asthma, nonallergic asthma, severe asthma, mild asthma, chronic obstructive pulmonary disease (COPD), a condition involving airway inflammation, cystic fibrosis, allergic lung disease, airway hyperresponsiveness, goblet cell metaplasia, mucus hypersecretion, airway remodeling, pulmonary fibrosis, atopic dermatitis,

urticaria, eczema, allergic enterogastritis, allergic rhinitis, inflammatory bowel diseases, liver cirrhosis or fibrosis, or a combination thereof.